MCK Quote, Financials, Valuation and Earnings

Cardinal Health, Inc. has a net margin of 1.13% compared to McKesson Corp.'s net margin of 0.71%. McKesson Corp.'s return on equity of -- beat Cardinal Health, Inc.'s return on equity of --.

McKesson Corp. has a consensus price target of $945.33, signalling upside risk potential of 13.73%. On the other hand Cardinal Health, Inc. has an analysts' consensus of $234.20 which suggests that it could grow by 8.99%. Given that McKesson Corp. has higher upside potential than Cardinal Health, Inc., analysts believe McKesson Corp. is more attractive than Cardinal Health, Inc..

McKesson Corp. has a beta of 0.408, which suggesting that the stock is 59.158% less volatile than S&P 500. In comparison Cardinal Health, Inc. has a beta of 0.644, suggesting its less volatile than the S&P 500 by 35.629%.

McKesson Corp. has a quarterly dividend of $0.82 per share corresponding to a yield of 0.37%. Cardinal Health, Inc. offers a yield of 0.95% to investors and pays a quarterly dividend of $0.51 per share. McKesson Corp. pays 10.69% of its earnings as a dividend. Cardinal Health, Inc. pays out 31.43% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

McKesson Corp. quarterly revenues are $103.2B, which are larger than Cardinal Health, Inc. quarterly revenues of $64B. McKesson Corp.'s net income of $1.2B is higher than Cardinal Health, Inc.'s net income of $454M. Notably, McKesson Corp.'s price-to-earnings ratio is 25.88x while Cardinal Health, Inc.'s PE ratio is 32.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for McKesson Corp. is 0.27x versus 0.22x for Cardinal Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cencora, Inc. has a net margin of 1.13% compared to McKesson Corp.'s net margin of -0.4%. McKesson Corp.'s return on equity of -- beat Cencora, Inc.'s return on equity of 124.72%.

McKesson Corp. has a consensus price target of $945.33, signalling upside risk potential of 13.73%. On the other hand Cencora, Inc. has an analysts' consensus of $399.07 which suggests that it could grow by 11.09%. Given that McKesson Corp. has higher upside potential than Cencora, Inc., analysts believe McKesson Corp. is more attractive than Cencora, Inc..

McKesson Corp. has a beta of 0.408, which suggesting that the stock is 59.158% less volatile than S&P 500. In comparison Cencora, Inc. has a beta of 0.664, suggesting its less volatile than the S&P 500 by 33.595%.

McKesson Corp. has a quarterly dividend of $0.82 per share corresponding to a yield of 0.37%. Cencora, Inc. offers a yield of 0.63% to investors and pays a quarterly dividend of $0.60 per share. McKesson Corp. pays 10.69% of its earnings as a dividend. Cencora, Inc. pays out 27.63% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

McKesson Corp. quarterly revenues are $103.2B, which are larger than Cencora, Inc. quarterly revenues of $83.7B. McKesson Corp.'s net income of $1.2B is higher than Cencora, Inc.'s net income of -$333.1M. Notably, McKesson Corp.'s price-to-earnings ratio is 25.88x while Cencora, Inc.'s PE ratio is 45.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for McKesson Corp. is 0.27x versus 0.22x for Cencora, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Standard BioTools, Inc. has a net margin of 1.13% compared to McKesson Corp.'s net margin of -162.05%. McKesson Corp.'s return on equity of -- beat Standard BioTools, Inc.'s return on equity of -24.44%.

McKesson Corp. has a consensus price target of $945.33, signalling upside risk potential of 13.73%. On the other hand Standard BioTools, Inc. has an analysts' consensus of $1.55 which suggests that it could grow by 10.71%. Given that McKesson Corp. has higher upside potential than Standard BioTools, Inc., analysts believe McKesson Corp. is more attractive than Standard BioTools, Inc..

McKesson Corp. has a beta of 0.408, which suggesting that the stock is 59.158% less volatile than S&P 500. In comparison Standard BioTools, Inc. has a beta of 1.264, suggesting its more volatile than the S&P 500 by 26.42%.

McKesson Corp. has a quarterly dividend of $0.82 per share corresponding to a yield of 0.37%. Standard BioTools, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. McKesson Corp. pays 10.69% of its earnings as a dividend. Standard BioTools, Inc. pays out -- of its earnings as a dividend. McKesson Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

McKesson Corp. quarterly revenues are $103.2B, which are larger than Standard BioTools, Inc. quarterly revenues of $19.6M. McKesson Corp.'s net income of $1.2B is higher than Standard BioTools, Inc.'s net income of -$31.7M. Notably, McKesson Corp.'s price-to-earnings ratio is 25.88x while Standard BioTools, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for McKesson Corp. is 0.27x versus 4.12x for Standard BioTools, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pineapple, Inc. has a net margin of 1.13% compared to McKesson Corp.'s net margin of -184.62%. McKesson Corp.'s return on equity of -- beat Pineapple, Inc.'s return on equity of --.

McKesson Corp. has a consensus price target of $945.33, signalling upside risk potential of 13.73%. On the other hand Pineapple, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that McKesson Corp. has higher upside potential than Pineapple, Inc., analysts believe McKesson Corp. is more attractive than Pineapple, Inc..

McKesson Corp. has a beta of 0.408, which suggesting that the stock is 59.158% less volatile than S&P 500. In comparison Pineapple, Inc. has a beta of 41.025, suggesting its more volatile than the S&P 500 by 4002.548%.

McKesson Corp. has a quarterly dividend of $0.82 per share corresponding to a yield of 0.37%. Pineapple, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. McKesson Corp. pays 10.69% of its earnings as a dividend. Pineapple, Inc. pays out -- of its earnings as a dividend. McKesson Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

McKesson Corp. quarterly revenues are $103.2B, which are larger than Pineapple, Inc. quarterly revenues of $1.3K. McKesson Corp.'s net income of $1.2B is higher than Pineapple, Inc.'s net income of -$2.4K. Notably, McKesson Corp.'s price-to-earnings ratio is 25.88x while Pineapple, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for McKesson Corp. is 0.27x versus 52.83x for Pineapple, Inc.. Usually stocks with elevated PS ratios are considered overvalued.